Nonneutralizing antibody against the glycoprotein K of herpes simplex virus type-1 exacerbates herpes simplex virus type-1-induced corneal scarring in various virus-mouse strain combinations

Investigative Ophthalmology and Visual Science

Volumn 38, Issue 6, 1997, Pages 1213-1221

  Ghiasi, Homayon ^a,b   Cai, Steve ^a   Slanina, Susan ^a   Nesburn, Anthony B ^a,b   Wechsler, Steven L ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

eye disease; glycoproteins; HSV 1; mice; ocular; vaccine

Indexed keywords

IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORNEA DISEASE; FEMALE; HERPES SIMPLEX VIRUS 1; MOUSE; MOUSE STRAIN; NONHUMAN; PASSIVE TRANSPORT; PRIORITY JOURNAL; SCAR FORMATION; T LYMPHOCYTE; VACCINATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES; BACULOVIRIDAE; CICATRIX; CORNEA; IMMUNOGLOBULIN G; KERATITIS, HERPETIC; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SIMPLEXVIRUS; SPECIES SPECIFICITY; T-LYMPHOCYTES; VACCINATION; VIRAL PROTEINS;

EID: 0030914917     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Stevens JG. Human herpesviruses: A consideration of the latent state. Microbiol Rev. 1989; 53:318-332.
2. Margolis P, Sedarati F, Dobson AT, Feldman LT, Stevens JG. Pathways of viral gene expression during acute neuronal infection with HSV-1. Virology. 1992; 189:150-160.
3. Rodahl E, Stevens JG. Differential accumulation of herpes simplex virus type-1 latency-associated transcripts in sensory and autonomic ganglia. Virology. 1992;189:385-388.
4. Rock DL, Nesburn AB, Ghiasi H, et al. Detection of latency related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1. J Virol. 1987; 61:3820-3826.
5. Wechsler SL, Nesburn AB, Watson RJ, Slanina S, Ghiasi H. Fine mapping of the major latency related-RNA of herpes simplex virus type 1 in humans. J Gen Virol. 1988; 69:3101-3106.
6. Corey L, Spear PG. Infections with Herpes Simplex Viruses. N Engl J Med. 1986; 314:686-691.
7. Cobo M. Herpes simplex infections. Mayo Clin Proc. 1988; 63:1154-1156.
8. Dix RD. Prospects for a vaccine against herpes simplex virus types 1 and 2. Prog Med Virol. 1987; 34:89-128.
9. Stanberry LR. Herpesvirus latency and recurrence. Prog Med Virol. 1986; 33:61-77.
10. Binder PS. Herpes simplex keratitis. Surv Ophthalmol. 1977; 21:313-331.
11. Dawson CR, Togni B. Herpes simplex eye infections: Clinical manifestations, pathogenesis and management. Surv Ophthalmol. 1976; 21:121-135.
12. Nesburn AB. Recurrent herpes simplex infection: Pathogenesis and treatment. In: Barraquer JI, Binder PS, Buxton JN, et al. Symposium on Medical and Surgical Diseases of the Cornea. St. Louis: CV Mosby Company; 1980:48-68.
13. Metcalf JF, Kaufman HE. Herpetic stromal keratitisevidence for cell-mediated immunopathogenesis. Am J Ophthalmol. 1976: 82:827-834.
14. Hendricks RL, Tumpey TM. Contribution of virus and immune factors to Herpes simplex virus type 1 induced corneal pathology. Invest Ophthalmol Vis Sci. 1990; 31:1929-1939.
15. Niemialtowski MG, Rouse BT. Phenotypic and functional studies on ocular T cells during herpetic infections of the eye. J Immunol. 1992; 148:1864-1870.
16. Newell CK, Martin S, Sendele D, Mercadal CM, Rouse BT. Herpes simplex virus-induced stromal keratitis: Role of T-lymphocyte subsets in immunopathology. J Virol. 1989; 63:769-775.
17. Stroop WG, Schaefer DC. Severity of experimentally reactivated herpetic eye disease is related to the neurovirulence of the latent virus. Invest Ophthalmol Vis Sci. 1987; 28:229-237.
18. Berman EJ, Hill JM. Spontaneous ocular shedding of HSV-1 in latently infected rabbits. Invest Ophthalmol Vis Sci. 1985; 26:587-590.
19. Nesburn AB, Elliott JM, Leibowitz HM. Spontaneous recurrence of experimental herpes simplex keratitis in rabbits. Arch Ophthalmol Vis Sci. 1980; 19:267-270.
20. Shimeld C, Hill TJ, Blyth WA, Easty DL. An improved model of recurrent herpetic eye disease in mice. Curr Eye Res. 1989; 8:1193-1205.
21. Shimeld C, Hill TJ, Blyth WA, Easty DL. Reactivation of latent infection and induction of recurrent herpetic eye disease in mice. J Gen Virol. 1990; 71:397-404.
22. Laycock KA, Lee SF, Brady RH, Pepose JS. Characterization of a murine model of recurrent herpes simplex viral keratitis induced by ultraviolet B radiation. Invest Ophthalmol Vis Sci. 1991; 32:2741-2746.
23. Norrild B. Humoral response to herpes simplex virus infections. In: Roizman B, Lopez C, eds. The Herpesviruses. New York: Plenum Press; 1985:69-86.
24. Nash AA, Cambouropoulos P. The immune response to herpes simplex virus. Virology. 1993; 4:181-186.
25. Ghiasi H, Slanina S, Nesburn AB, Wechsler SL. Characterization of baculovirus expressed herpes simplex virus type 1 glycoprotein K (gK).J Virol. 1994; 68:2347-2354.
26. Ghiasi H, Kaiwar R, Nesburn AB, Slanina S, Wechsler SL. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH and gI): Comparative protection against lethal challenge in mice, J Virol. 1994; 68:2118-2126.
27. Ghiasi H, Bahri S, Kaiwar R, Nesburn AB, Slanina S, Wechsler SL. Protection against HSV induced eye disease following vaccination with 7 individually expressed HSV-1 glycoproteins. Invest Ophthalmol Vis Sci. 1995; 36:1352-1360.
28. Ghiasi H, Kaiwar R, Slanina S, Nesburn AB, Wechsler SL. Expression and characterization of baculovirus expressed Herpes simplex virus type 1 glycoprotein L. Arch Virol. 1994; 138:199-212.
29. Hendricks RL, Tumpey TM, Finnegan A. IFN-gamma and IL-2 are Protective in the Skin But Pathologic in the Corneas of HSV-1-Infected Mice. J Immunol. 1992; 149:3023-3028.
30. Wechsler SL, Nesburn AB, Watson RJ, Slanina SM, Ghiasi H. Fine mapping of the latency related gene of herpes simplex virus type 1: Alternative splicing produces distinct latency related-RNAs containing open reading frames. J Virol 1988; 62:4051-4058.
31. Hill JM, Dudley JB, Shimomura Y, Kaufman HE. Quanti talion and kinetics of induced HSV-1 ocular shedding. Curr Eye Res. 1986; 5:241-246.
32. Cosgrove D, Gray D, Dierich A, et al. Mice lacking MHC class II molecules. Cell 1991; 66:1051-1066.
33. Nesburn AB, Green MT. Recurrence in ocular herpes simplex infection. Invest Ophthalmol. 1976; 15:515-518.
34. Ghiasi H, Cai S, Nesburn AB, Wechsler SL. Vaccination with herpes simplex virus type 1 glycoprotein K impairs clearance of virus from the trigeminal ganglia resulting in chronic infection. Virology. 1996; 224:330-333.
35. Kotwal GJ, Isaacs SN, McKenzie R, Frank MM, Moss B. Inhibition of the complement cascade by the major secretory protein of vaccinia-virus. Science. 1990; 250: 827-829.
36. Alcami A, Smith GL. A soluble receptor for interleukin-1B encode by vaccinia virus: A novel mechanism of virus modulation of the host response to infection. Cell 1992; 71:153-167.
37. Spriggs MK, Koller BH, Sato T, et al. Beta2-microglobulin-, CD8 T-cell deficient mice survive inoculation with high doses of vaccinia virus and exhibit altered IgG responses. Proc Natl Acad Sci USA. 1992; 89:6070-6074.
38. Gooding LR. Virus protein that counteract host immune-defenses. Cell. 1992; 71:5-7.
39. Hsu DH, de Waal Malefyt R, Fiorentino DF, et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science. 1990; 250:830-832.
40. Hill A, Jugovic P, Russ G, et al. HSV turns of the TAP to evade host immunity. Nature (London). 1995; 375:411-415.
41. + T lymphocytes. Cell. 1994; 77:525-535.
42. Harris SL, Frank I, Yee A, Cohen GH, Eisenberg RJ, Friedman HM. Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization. J Infect. Dis. 1990;162:331-337.
43. Hung SL, Srinivasan S, Friedman HM, Eisenberg RJ, Cohen GH. Structural basis of C3b binding by glycoproteinC of herpes simplex virus. J Virol 1992; 66:4013-4027.
44. Seidel-Dugan C, Ponce de Leon M, Friedman HM, et al. C3b receptor activity on transfected cells expressing glycoprotein C of herpes simplex virus types 1 and 2. J Virol. 1988; 62:4027-4036.
45. Ghiasi H, Kaiwar R, Nesburn AB, Wechsler SL. Baculovirus expressed Herpes simplex virus type I glycoprotein C protects mice from lethal HSV-1 infection. Antiviral Res. 1992; 18:291-302.
46. Frank I, Friedman HM. A novel function of the herpes simplex virus type 1 Fc receptor: Participation in bipolar bridging of antiviral immunoglobulin G. J Virol. 1989; 63:4479-4488.
47. Adler R, Glorioso JC, Cossman J, Levin M. Possible role of Fc receptors on cells infected and transformed by herpesvirus: Escape from immune cytolysis. Infect Immun. 1978; 21:442-447.
48. Oakes JE, Lausch RN. Role of Fc fragments in antibody-mediated recovery from ocular and subcutaneous herpes simplex virus infections. Infect Immun. 1981; 33:109-114.
49. Johnson DC, Feenstra V. Identification of a novel Herpes Simplex Virus Type 1-induced glycoprotein which complexes with gE and binds immunoglobulin. J Virol. 1987; 61:2208-2216.
50. Wang SZ-S, Rushlow KE, Issel CJ, et al. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology. 1994; 199:247-251.
51. Hutchinson L, Roop-Beauchamp C, Johnson DC. Herpes simplex virus glycoproteins K is known to influence fusion of infected cells, yet is not on the cell surface. J Virol. 1995; 69:4556-4563.
52. Hutchinson L, Goldsmith K, Snoddy D, Ghosh H, Graham FL, Johnson DC. Identification and characterization of a novel herpes simplex virus glycoprotein, gK, involved in cell fusion. J Virol 1992; 66:5603-5609.